Tag Archives: GDUFA

New Fees Made FDA Worse for Generic Drug Approvals, Says GPhA Chairman

‘Actions’ don’t speak louder than words in dealing with FDA’s backlog of generic drug applications, says newly-elected GPhA Board Chairman Craig Wheeler. When the Generic Drug User Fee Act (GDUFA) was signed into law on July 7, 2012, its primary intent was to provide FDA with the additional resources necessary to expedite the review process […]
Posted in FDA, Legal, Market Access, People, R&D, Regulatory, Strategy | Also tagged , , , , , | Leave a comment

Budget policies jeopardize FDA funding, user fees

Budget policies jeopardize FDA funding, user fees Even though Congress authorized both existing and new user fees for the Food and Drug Administration several months ago through the FDA Safety & Innovation Act (FDASIA), efforts to cut the federal deficit raises questions about how those fees will be collected and used in the coming year. […]
Posted in FDA, Guest Blog, Regulatory | Also tagged , , , , , | Leave a comment
  • Categories

  • Meta